Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12772356 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT | |
| SCHEMBL31287272 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT | |
| SCHEMBL1537645 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT | |
| SCHEMBL6050963 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT | |
| SCHEMBL12530114 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT | |
| SCHEMBL380051 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT | |
| SCHEMBL2617514 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT | |
| SCHEMBL2617503 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT | |
| SCHEMBL8002198 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT | |
| SCHEMBL1673987 | 0.90 | MEN1 (0.38) | MEN1MAPK1KMT2ABTKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113088198-A | Shoe polish prepared from lanolin extract and preparation method thereof | 浙江花园营养科技有限公司 | 2021-07-09 | — | — | CN | claimed |
| CN-119930740-A | Dipeptide compound, chimeric molecule based on dipeptide compound and application of dipeptide compound | 西南交通大学 | 2025-05-06 | — | — | CN | disclosed |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-119264505-A | High-resilience soft foaming polyethylene material and preparation method thereof | 杭州锦煌科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4122537-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3938047-B1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114560857-A | Pyrimidopyridine compound and application thereof in medicine | 广东东阳光药业有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20050143316-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
| WO-2005051410-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| US-6878722-B2 | Substituted cycloalkyl P1′ hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-6869964-B2 | Heterocyclicsulfonamide hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1505945-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-20040072761-A1 | Heterocyclicsulfonamide hepatitis C virus inhibitors | CAMPBELL JEFFREY ALLEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040048802-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072761-A1 | Heterocyclicsulfonamide hepatitis C virus inhibitors | HCCS, ANPEP, DNPEP | MEN1 4196/4885MAPK1 3138/4885KMT2A 4022/4885 |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | MEN1 3841/4885MAPK1 4169/4885KMT2A 2126/4885 |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | MEN1 3841/4885MAPK1 4169/4885KMT2A 2126/4885 |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | MEN1 3841/4885MAPK1 4169/4885KMT2A 2126/4885 |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | MEN1 3841/4885MAPK1 4169/4885KMT2A 2126/4885 |
| US-20050143316-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, CTRB1 | MEN1 4820/4885MAPK1 2557/4885KMT2A 4052/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | MEN1 4817/4885MAPK1 1573/4885KMT2A 4220/4885 |
| US-20040048802-A1 | Hepatitis C virus inhibitors | HAVCR2, ZC3HAV1, VIP | MEN1 4575/4885MAPK1 3677/4885KMT2A 4483/4885 |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | HAVCR2, ANPEP, ENPEP | MEN1 4174/4885MAPK1 3703/4885KMT2A 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.